// App-Quantinova.ai

P1-09-19 : Tumor RNA disruption index as a tool to predict response to neoadjuvant chemotherapy in breast cancer: Optimizing timing of biopsy

Researchers

Presenter

  • A Samkari

Principal Investigators

  • W Chung

  • A Parissenti

  • L Pritzker

  • N Trabulsi

  • M Basik

  • J-F Boileau

Medical Centers

  • Northeast Cancer Ctr., Sudbury, Ontario, Canada.

  • Jewish General Hospital, Montreal, QC, Canada

  • Kingston General Hospital, Kingston, ON, Canada

Locations

  • Canada

Companies

  • Rna Diagnostics Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved